A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)
Latest Information Update: 08 Jul 2024
Price :
$35 *
At a glance
- Drugs Parsaclisib (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms CITADEL-205
- Sponsors Incyte Corporation
- 24 Jun 2024 Status changed from active, no longer recruiting to completed.
- 05 Jun 2024 This trial has been completed in Czech Republic.
- 19 Jan 2024 This study has been completed in Denmark.